Skip to main content
Equibles
PRLD logo

PRLD · Prelude Therapeutics Inc

Track PRLD — free

Use PRLD with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PRLD

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$5.55 +0.19 (+3.54%) At close · Aug 14
Market Cap
$442.91M
Shares
79.80M

Prelude Therapeutics Inc Earnings Call Transcripts

Every quarterly earnings call for Prelude Therapeutics Inc (PRLD) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $3.00M −$32.27M '24 Q3 24-12-02 · $ −$32.09M '25 Q1 25-05-06 ▲116.7% $6.50M −$19.73M '25 Q3 25-11-12 LATEST · $5.64M −$16.46M '25 Q4 26-03-10
Conference
Investor event
2026-06-10
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
2026 Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-10
Prelude Therapeutics Inc Q4 FY2025 Earnings Call
Revenue
$5.64M*
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Prelude Therapeutics Inc Q3 FY2025 Earnings Call
Positive tone CAP-6A selective degrader program JAK2V617F selective inhibitor program Clinical development timing / regulatory risk
Revenue
$6.50M
▲ 116.7% YoY
Diluted EPS
$-0.26
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Prelude Therapeutics Inc Q1 FY2025 Earnings Call
Revenue
$
Diluted EPS
$-0.42
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-10
Prelude Therapeutics Inc Q4 FY2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-12-02
Prelude Therapeutics Inc Q3 FY2024 Earnings Call
Revenue
$3.00M
Diluted EPS
$-0.43
Audio Transcript Slides 8-K10-Q
Showing 1–7 of 7 earnings calls
Key facts CIK 1678660 CUSIP 74065P101 13F (30d) 78 filings 78 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)